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Abstract: Over the last decades medicine has developed tremendously, but still many diseases are incurable. The last years,
cellular (gene) therapy has become a hot topic in biomedical research for the potential treatment of cancer, AIDS and diseases
involving cell loss or degeneration. Here, we will focus on two major areas within cellular therapy, cellular immunotherapy
and stem cell therapy, that could benefit from the introduction of neo-expressed genes through mRNA electroporation for basic
research as well as for clinical applications. For cellular immunotherapy, we will provide a state-of-the-art on loading
antigen-presenting cells with antigens in the mRNA format for manipulation of T cell immunity. In the area of stem cell
research, we will highlight current gene transfer methods into adult and embryonic stem cells and discuss the use of mRNA
electroporation for controlling guided differentiation of stem cells into specialized cell lineages.
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Introduction
The knowledge of medicine, immunology and biotechnol-
ogy has progressed enormously, but still many diseases are
incurable and have a large impact on the quality of life.
Therefore many scientists are looking for new treatments
for several diseases, like cancer, auto-immune diseases,
pandemic infections (e.g. HIV), neurodegenerative dis-
eases, etc. Several different approaches are studied, e.g.
new sorts of drugs and combinations of radiotherapy and
chemotherapy, but during the last years much attention has
been paid to custom-made cellular therapies. In this review
we will focus on the application of cellular therapy and
mRNA electroporation in different cell types for the poten-
tial treatment of various diseases.
Use of mRNA electroporation for
immunotherapy
The concept of immunotherapy in cancer and infectious
diseases is based on the body’s natural defence system that
protects us against a variety of diseases and is a therapy
that attempts to modify or enhance immune responses. The
most studied cell types for immunotherapy are antigen-
presenting cells (APC) and T cells, which are pivotal
players in initiating immune responses. Different
strategies have been developed for loading APC with
tumor or viral antigens [37]. Loading of characterized
antigenic peptides is the most straightforward way, how-
ever disadvantages are the prior knowledge of the pep-
tide epitopes, the short half-life of the human leukocyte
antigen (HLA)/peptide complexes and the dependence
on screening for appropriate HLA haplotypes in individ-
ual patients. Alternatively, viral and non-viral gene
transfer technologies can be used. Recombinant viral
vectors are characterized by a high transduction effi-
ciency, but pose biosafety risks for clinical application;
while transduction efficiency with viral vectors is high
[10], plasmid DNA transfer into dendritic cells (DC),
despite high clinical potential, has not been very efficient
[34]. Nonviral non-DNA based gene delivery has sev-
eral advantages, as compared to plasmid DNA and viral
vectors, since there is no danger of insertional mutagen-
esis, no viral antigens and absence of vector-induced
immunogenicity. The first report on the use of mRNA
to load APC has come from the group of E. Gilboa
[2,4,18]. The group of Gilboa applied passive RNA
pulsing or RNA lipofection to introduce the coding RNA
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into DC. Our group was the first to describe an optimized
electroporation protocol for the introduction of RNA
into DC providing both biochemical evidence of trans-
fection in terms of transgene EGFP expression as well
as evidence of major histocompatibility complex
(MHC) class I presentation [33]. Moreover, we demon-
strated that mRNA electroporation of human DC was
more efficient than plasmid DNA electroporation, and
lipofection or passive pulsing of RNA for stimulation of
antigen-specific CD8+ T cells, as confirmed by several
other groups [11, 15, 27]. 
Dendritic cells
Thus far, most reports on mRNA electroporation have
used dendritic cells (DC). As ’professional’ antigen-
capturing cells in an immature state and antigen-presen-
ting cells after maturation, they play an important role
in the activation of innate and adaptive immunity to
pathogens, as well as in the maintenance of peripheral
tolerance [30]. Especially the expression of costimula-
tory molecules on DC provides an extra immune stimu-
lating signal to initiate a more efficient immune
response. DC can be cultured from peripheral blood
monocytes and therefore are readily accessible for use
in cellular therapy. Antigen processing and subsequent
MHC class I presentation on DC membrane after mRNA
electroporation could be demonstrated using a CD8+ T
cell clone for MAGE-A1 [24], Melan A [33] and WT1
(unpublished results). Transfection of mRNA encoding
influenza (flu) matrix protein M1 allows loading of
monocytes or DC for induction of autologous flu-spe-
cific CD8+ T cell activation [20, 22, 25]. After
cryopreservation, mRNA-electroporated DC retained
transgene expression, phenotypic properties and, most
importantly, stimulatory capacity [25]. Recently, more
reports on in vitro activation using RNA-electroporated
dendritic cells have been published, generally regarding
cancer-related antigens, e.g. telomerase [27], Melan A
[11], total myeloma cell RNA [17]. Recently, we have
observed that electroporation of HIV-1 gag mRNA can
activate memory T cells from HIV patients ex vivo
(unpublished results). Patients’ autologous proviral
DNA was PCR-amplified and DC electroporated with
in vitro transcribed proviral gag mRNA stimulated auto-
logous T cells. These findings open a major perspective
for the development of patient-specific immunotherapy
directed against the entire latent HIV quasispecies.
The loading of cells with mRNA is not only useful to
transfect antigens, but can also be used to introduce
costimulatory molecules in dendritic cells, like toll-like
receptor (TLR) 4 [1, 5] and OX40L [7].
The use of mRNA-loaded DC has been very success-
ful in in vitro experiments and now this strategy has been
translated into several clinical trials. Cytotoxic T lym-
phocyte (CTL) responses were obtained in patients with
metastatic prostate tumors after vaccination with DC
passively pulsed with prostate-specific antigen mRNA
[9]. Nair et al. showed that vaccination with DC trans-
fected with total tumor-derived mRNA stimulated a
tumor-specific immune response in a patient with a
carcino-embryonic antigen (CEA)-expressing adeno-
carcinoma [19]. Other clinical trials using RNA-loaded
DC are still ongoing. We are currently recruiting acute
myeloid leukemia (AML) patients in remission for a
vaccine trial using WT1 mRNA-electroporated DC.
CD40-activated B cells
B cells are an alternative for DC and can be obtained
from small quantities of peripheral blood. In contrast to
the culture of DC starting from monocytes, B cells can
proliferate and massive amounts can be cultured in vitro
by CD40 activation, which makes them a cost-effective
alternative for DC [28]. CD40-activated (CD40-) B cells
have been shown in several in vitro systems to activate
CTL responses against viral and tumor antigen targets,
including neoantigens, that are formulated as peptides,
proteins, or viral vectors [3, 12, 14]. Coughlin et al.
reported that CD40-B cells transfected with RNA may
serve as an alternative vaccine that can be generated
from small blood volumes regardless of patient age [6].
They cultured CD40-B cells from pediatric patients with
neuroblastoma and elicited cytotoxic T cells against
several neuroblastoma-related antigens using tumor
RNA-electroporated CD40-B cells. CD40-B cells can
also be used to elicit CTL responses against infectious
agents as demonstrated by Van den Bosch et al. for
cytomegalovirus and influenza [31]. 
T cells
In the field of adoptive T cell immunotherapy, mRNA-
based gene transfer into T cells could prove useful. Our
group demonstrated that mRNA electroporation is feas-
ible in activated T cells. However, in unstimulated T
cells, mRNA electroporation turned out to be relatively
inefficient [29].
Use of mRNA electroporation in stem cell
research
Stem cell research, both embryonic and adult, offers
several prospects towards the development of future
cell-based therapies in regenerative medicine. The hope
exists that (stem) cell transplantation will become part
of an effective therapy for neurological disease or injury,
diabetes and myocardial infarction. Although various
combinations of growth factors and chemicals have been
described for in vitro differentiation of stem cells into
specific cell types, novel research is now focusing on the
development of gene-based strategies in order to control
and/or direct in vivo differentiation of transplanted stem
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cell populations. For this, viral transduction techniques
have been described as highly efficient for genetic modi-
fication of adult and embryonic stem cell populations [8,
16, 35], while currently optimized non-viral plasmid
DNA-based transfection methods do not result in excep-
tionally high gene transfer efficiencies [13, 36]. As
described before, one should consider the use of non-
viral gene transfer methods when looking forward to
clinical applications. In this context, we have investi-
gated and introduced potential applications of mRNA-
based gene transfer in stem cell research.
RNA-based gene transfer for adult 
and embryonic stem cells
For adult stem cell populations, we have shown that
mRNA electroporation is a highly efficient gene transfer
technology for in vitro cultured human bone marrow
stromal cells (90% of gene transfer efficiency) and can
also be used, although less efficiently at this time, for
genetic loading of human CD34+ hematopoietic stem
cells (35% of gene transfer efficiency) [29]. For em-
bryonic stem cell populations, we demonstrated highly
efficient cytoplasmic gene expression in 80-90% of mouse
and human embryonic carcinoma (EC) stem cells (unpub-
lished data) and mouse and human embryonic stem (ES)
cells after electroporation with in vitro transcribed mRNA
[21, 23, 26]. Moreover, next to the possibility of short term
gene transfer via direct mRNA electroporation, electropor-
ation with mRNA encoding Cre- or FLPe-recombinase
proteins provides an easy and highly efficient method to
induce sustained transgene expression in whole ES cell
populations stably transfected with LoxP and/or FRT-
flanked target sequences [21, 32]. 
Directing stem cell differentiation via
RNA-based gene transfer
One of the research lines in our laboratory aims to
investigate whether directed neural differentiation of em-
bryonic cells can be induced after electroporation with
mRNA encoding neural transcription factors and/or
growth factors. In preliminary experiments, mouse P19 EC
stem cells were electroporated with mRNA encoding vari-
ous neurotrophic factors. Next, mRNA-electroporated P19
EC stem cells were allowed to form embryoid bodies
during 4 days followed by flow cytometric analysis for the
presence of neural progenitor cells based on A2B5 stai-
ning. While mock electroporation or electroporation with
mRNA encoding EGFP, brain-derived neurotrophic factor
(BDNF) and glial cell-derived neurotrophic factor
(GDNF) did not result in directed neural differentiation,
electroporation with mRNA encoding neurotrophin-3
(NT3) or electroporation with a mixture of BDNF, GDNF
and NT3 mRNA resulted in an increased number of
A2B5+ neural progenitor cells within cultured embryoid
bodies (unpublished data). These encouraging results on
P19 EC stem cells provide proof-of-principle for the
further development of RNA-based gene transfer
strategies for triggering stem cell differentiation. 
Conclusions and future perspectives
As outlined above, mRNA electroporation is a versatile
powerful tool for obtaining short-term transgene ex-
pression in a variety of cell types. The use of mRNA-
loaded DC has been very successful for in vitro purposes
and has been recently translated into several clinical
trials. The first results are very encouraging, as tumor
specific immune responses were elicited [9, 19]. Several
other clinical trials using RNA-loaded DC are still on-
going and will hopefully pave the way for improved DC
therapy of cancer, but also for infectious diseases.
Messenger RNA electroporation is a promising
method for genetic loading of stem cells with genes in
order to direct their differentiation towards specialized
cell types, which could be of use in the treatment of
various diseases. However, clinical applicability can
only be established after intensive laboratory studies,
both in vitro and in vivo, that should elaborate on the
safety and effectiveness of stem cell-based therapies.
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